Test Code LAB0288902 JAK2 V617F Mutation Detection, Blood
Additional Codes
Mayo Test ID |
---|
JAK2B |
Performing Laboratory
Mayo Clinic Laboratories in RochesterUseful For
Aiding in the distinction between a reactive blood cytosis and a chronic myeloproliferative disorder using peripheral blood specimens
Testing Algorithm
For more information see:
-Erythrocytosis Evaluation Testing Algorithm
-Myeloproliferative Neoplasm: A Diagnostic Approach to Peripheral Blood Evaluation
Special Instructions
Method Name
Quantitative Polymerase Chain Reaction (PCR)
Reporting Name
JAK2 V617F Mutation Detection, BSpecimen Type
Whole Blood EDTAShipping Instructions
Specimen must arrive within 7 days of collection.
Specimen Required
Container/Tube:
Preferred: Lavender top (EDTA)
Acceptable: Yellow top (ACD)
Specimen Volume: 4 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
Specimen Minimum Volume
1 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Whole Blood EDTA | Ambient (preferred) | 7 days | PURPLE OR PINK TOP/EDTA |
Refrigerated | 7 days | PURPLE OR PINK TOP/EDTA |
Reject Due To
Gross hemolysis | Reject |
Moderately to severely clotted | Reject |
Reference Values
An interpretive report will be provided.
Interpretation
The results will be reported as 1 of the 2 states:
-Negative for JAK2 V617F variant
-Positive for JAK2 V617F variant
Positive variant status is highly suggestive of a myeloid neoplasm but must be correlated with clinical and other laboratory features for definitive diagnosis.
Negative variant status does not exclude the presence of a myeloproliferative neoplasm or other neoplasm.
Results below the laboratory cutoff for positivity are of unclear clinical significance at this time.
Day(s) Performed
Monday through Saturday
Report Available
2 to 5 daysSpecimen Retention Time
Whole blood: 2 weeks; Extracted DNA: 3 monthsTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81270-JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, p.Val617Phe (V617F) variant
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
JAK2B | JAK2 V617F Mutation Detection, B | 43399-5 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
39722 | JAK2 Result | 53761-3 |
29590 | JAK2 V617F Mutation Detection, B | 43399-5 |
Forms
1. Hematopathology Patient Information (T676)
2. If not ordering electronically, complete, print, and send a Hematopathology/Cytogenetics Test Request (T726) with the specimen.